246 related articles for article (PubMed ID: 24717019)
21. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours.
Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J
Vet J; 2019 May; 247():71-74. PubMed ID: 30971355
[TBL] [Abstract][Full Text] [Related]
22. Epidemiological Study of Canine Mast Cell Tumours According to the Histological Malignancy Grade.
Śmiech A; Ślaska B; Łopuszyński W; Jasik A; Szczepanik M; Wilkołek P
Pol J Vet Sci; 2017 Sep; 20(3):455-465. PubMed ID: 29166281
[TBL] [Abstract][Full Text] [Related]
23. Cytologic features of testicular tumours in dog.
Masserdotti C; Bonfanti U; De Lorenzi D; Tranquillo M; Zanetti O
J Vet Med A Physiol Pathol Clin Med; 2005 Sep; 52(7):339-46. PubMed ID: 16109100
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours.
Donnelly L; Mullin C; Balko J; Goldschmidt M; Krick E; Hume C; Brown DC; Sorenmo K
Vet Comp Oncol; 2015 Mar; 13(1):70-6. PubMed ID: 23451809
[TBL] [Abstract][Full Text] [Related]
25. Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours.
Preziosi R; Sarli G; Paltrinieri M
Vet Res Commun; 2007 Apr; 31(3):287-96. PubMed ID: 17195927
[TBL] [Abstract][Full Text] [Related]
26. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers.
Gil da Costa RM; Matos E; Rema A; Lopes C; Pires MA; Gärtner F
BMC Vet Res; 2007 Aug; 3():19. PubMed ID: 17711582
[TBL] [Abstract][Full Text] [Related]
27. Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours.
Moore AS; Frimberger AE; Taylor D; Sullivan N
Vet Comp Oncol; 2020 Sep; 18(3):402-408. PubMed ID: 31916687
[TBL] [Abstract][Full Text] [Related]
28. Inclusion of fibroblasts and collagen fibrils in the cytologic grading of canine cutaneous mast cell tumors.
Paes PRO; Horta RS; Luza LC; Pierezan F; Costa MP; Lavalle GE
Vet Clin Pathol; 2022 Sep; 51(3):339-348. PubMed ID: 35419864
[TBL] [Abstract][Full Text] [Related]
29. Proliferative activity of canine mast cell tumours evaluated by bromodeoxyuridine incorporation and Ki-67 expression.
Sakai H; Noda A; Shirai N; Iidaka T; Yanai T; Masegi T; Shirai N; Iidaka T; Yanai T; Masegi T
J Comp Pathol; 2002 Nov; 127(4):233-8. PubMed ID: 12443730
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of bone marrow aspirates from multiple sites for staging of canine lymphoma and mast cell tumours.
Aubry OA; Spangler EA; Schleis SE; Smith AN
Vet Comp Oncol; 2014 Mar; 12(1):58-66. PubMed ID: 22577893
[TBL] [Abstract][Full Text] [Related]
31. Comparison between May-Grünwald-Giemsa and rapid cytological stains in fine-needle aspirates of canine mast cell tumour: Diagnostic and prognostic implications.
Sabattini S; Renzi A; Marconato L; Militerno G; Agnoli C; Barbiero L; Rigillo A; Capitani O; Tinto D; Bettini G
Vet Comp Oncol; 2018 Dec; 16(4):511-517. PubMed ID: 29961972
[TBL] [Abstract][Full Text] [Related]
32. HSP32 and HSP90 Immunoexpression, in Relation to Kit Pattern, Grading, and Mitotic Count in Canine Cutaneous Mast Cell Tumors.
Romanucci M; Massimini M; Ciccarelli A; Malatesta D; Bongiovanni L; Gasbarre A; Della Salda L
Vet Pathol; 2017 Mar; 54(2):222-225. PubMed ID: 27627984
[TBL] [Abstract][Full Text] [Related]
33. Patient and tumour factors influencing canine mast cell tumour histological grade and mitotic index.
Reynolds BD; Thomson MJ; O'Connell K; Morgan EJ; Gummow B
Vet Comp Oncol; 2019 Sep; 17(3):338-344. PubMed ID: 30891882
[TBL] [Abstract][Full Text] [Related]
34. Variation among pathologists in histologic grading of canine cutaneous mast cell tumors.
Northrup NC; Harmon BG; Gieger TL; Brown CA; Carmichael KP; Garcia A; Latimer KS; Munday JS; Rakich PM; Richey LJ; Stedman NL; Cheng AL; Howerth EW
J Vet Diagn Invest; 2005 May; 17(3):245-8. PubMed ID: 15945380
[TBL] [Abstract][Full Text] [Related]
35. Analysis of risk factors for canine mast cell tumors based on the Kiupel and Patnaik grading system among dogs with skin tumors.
Martins AL; Carvalho FF; Mesquita JR; Gärtner F; Amorim I
Open Vet J; 2021; 11(4):619-634. PubMed ID: 35070857
[TBL] [Abstract][Full Text] [Related]
36. Cytologic comparison of the percentage of mast cells in lymph node aspirate samples from clinically normal dogs versus dogs with allergic dermatologic disease and dogs with cutaneous mast cell tumors.
Mutz ML; Boudreaux BB; Royal A; Merchant S; Pucheu-Haston C; Griffith EH; Gieger TL
J Am Vet Med Assoc; 2017 Aug; 251(4):421-428. PubMed ID: 28763275
[TBL] [Abstract][Full Text] [Related]
37. Identification of two molecular subtypes in canine mast cell tumours through gene expression profiling.
Pulz LH; Barra CN; Alexandre PA; Huete GC; Cadrobbi KG; Nishiya AT; de Freitas SH; Fukumasu H; Strefezzi RF
PLoS One; 2019; 14(6):e0217343. PubMed ID: 31216299
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of lymph node metastasis with grade 2 MCTs in dogs: 55 cases (2001-2010).
Baginski H; Davis G; Bastian RP
J Am Anim Hosp Assoc; 2014; 50(2):89-95. PubMed ID: 24446400
[TBL] [Abstract][Full Text] [Related]
39. CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells.
Meyer A; Gruber AD; Klopfleisch R
Vet Pathol; 2012 Nov; 49(6):988-97. PubMed ID: 22446323
[TBL] [Abstract][Full Text] [Related]
40. Mast cell tumors in a llama (Lama glama).
Lin TY; Hamberg A; Pentecost R; Wellman M; Stromberg P
J Vet Diagn Invest; 2010 Sep; 22(5):808-11. PubMed ID: 20807950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
